MURAL
LIVE

Serial Number

97907917

Owner

Alkermes Pharma Ireland Limited

Attorney

Norm J. Rich

Filing Date

Apr 26, 2023

Add to watchlist:

No watchlists yet
View on USPTO

MURAL Trademark

Serial Number: 97907917

MURAL is a trademark filed by Alkermes Pharma Ireland Limited on April 26, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Alkermes Pharma Ireland Limited (87 trademarks)

Connaught House
Dublin 4 , IE

Entity Type: 99

MURAL ONCOLOGY, INC. (8 trademarks)

852 WINTER STREET
WALTHAM, MA 02451

Entity Type: 03

Trademark Details

Filing Date

April 26, 2023

Registration Date

Not Registered

Goods & Services

Providing educational information in the field of medication treatment for oncology to health care providers and patients, namely, providing information in the field of cancer prevention, screening, diagnosis and treatment

Therapeutic proteins for use in the manufacture of pharmaceutical preparations

Research and development of medicines for use in the fields of oncology-related diseases and disorders; Protein engineering for others for use in the development of pharmaceuticals; Protein structure modifications for others for use in the development of pharmaceuticals, namely, conducting pharmaceutical research and development of engineered protein therapeutic pharmaceuticals and biopharmaceuticals for others; Conducting medical and scientific research in the fields of oncology-related diseases and disorders for others; Conducting clinical medical research for others in the field of cancerous diseases and disorders; Clinical research in the field of cancerous diseases and disorders in the nature of research and development of pharmaceuticals and biopharmaceutical products for others; Scientific research in the field of cancerous diseases and disorders in the nature of research and development of pharmaceuticals and biopharmaceutical products for others; Providing information and data about medical and scientific research and development in the fields of pharmaceuticals, biopharmaceuticals, clinical trials, therapeutic proteins, and fusion proteins, used to treat cancerous diseases and disorders; Providing websites featuring medical and scientific research information about pharmaceutical and biopharmaceutical drugs and their preparations; Cytokine engineering and cytokine research and development for use in the development of pharmaceuticals, namely, conducting pharmaceutical research, engineering and products development for others in the fields of cancer, immunopharmaceuticals for use in the treatment of cancer and engineered cytokine therapeutic pharmaceuticals and bio-pharmaceuticals for use in the treatment of cancer and cancer-related disorders; Conducting scientific research for others in the field of cytokine biology for use in pharmaceutical research and development; Scientific research and development of immune modulating proteins for others for use in the development of pharmaceuticals; Scientific research and development for others of cytokine based biopharmaceutical treatments for oncology-related diseases and disorders; Conducting protein based therapeutic medical research and pharmaceutical products development for others in the field of pharmaceuticals and biopharmaceuticals for the treatment of cancer and related diseases and disorders; Protein or cytokine based cancer immunotherapy research and development, namely, conducting pharmaceutical research and products development for others in the field of cancer; Providing educational information in the field of medication treatment for oncology to health care providers and patients, namely, providing medical and scientific research information about clinical trials featuring pharmaceutical treatments in the field of oncology

Biopharmaceutical active substances, namely, pharmaceutical preparations and substances for the treatment of oncological-related diseases and disorders; Biological preparations for the treatment of cancer; Engineered fusion proteins for medical diagnostic and treatment purposes, namely, engineered fusion proteins created through the use of circular permutation technology for use in the treatment of cancer and cancer-related disorders; Engineered interleukin protein pharmaceutical preparations for use in optimizing patients' immune cellular response to prevent cancer-associated morbidity and mortality; Pharmaceutical preparations, namely, tumor-targeted immunotherapeutic fusion proteins for the treatment of cancer and cancer-related disorders; Cytokine inhibitory pharmaceutical and biological preparations for use in the treatment of oncology-related diseases and disorders; Biological and chemical immunotherapy preparations comprising anti-body-cytokine fusion protein pharmaceutical preparations for use in the medical treatment and prevention of cancer

Filing History

REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Oct 29, 2025 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Apr 28, 2025 RCSC
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Oct 28, 2024 GNS3
LETTER OF SUSPENSION E-MAILED
Oct 28, 2024 GNSL
SUSPENSION LETTER WRITTEN
Oct 28, 2024 CNSL
EXAMINER'S AMENDMENT ENTERED
Oct 28, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 28, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Oct 28, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Oct 28, 2024 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 12, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 12, 2024 CRFA
ASSIGNED TO LIE
Sep 12, 2024 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 23, 2024 TROA
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Feb 28, 2024 ASGN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 25, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jan 25, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jan 25, 2024 CNRT
ASSIGNED TO EXAMINER
Jan 23, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 24, 2023 NWOS
NEW APPLICATION ENTERED
May 1, 2023 NWAP